Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of TAK-003 in Healthy Adolescents in Non-Endemic Areas
NCT03341637Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Started Dec 2017; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03341637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341637.